Appropriate statistical methods are available to handle biases encountered in blinded, independent, central review (BICR) determined progression-free survival.

作者信息

Lavery Jessica A, Panageas Katherine S

机构信息

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

出版信息

J Hosp Manag Health Policy. 2019 Apr;3. doi: 10.21037/jhmhp.2019.04.01. Epub 2019 Apr 9.

DOI:10.21037/jhmhp.2019.04.01

PMID:31304462

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6625798/

Abstract

摘要

相似文献

[1]

Appropriate statistical methods are available to handle biases encountered in blinded, independent, central review (BICR) determined progression-free survival.

J Hosp Manag Health Policy. 2019-4

[2]

Evaluation of Blinded Independent Central Review of Tumor Progression in Oncology Clinical Trials: A Meta-analysis.

Ther Innov Regul Sci. 2013-3

[3]

Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis.

Eur J Cancer. 2011-3-21

[4]

Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial.

Gynecol Oncol. 2014-11-28

[5]

Testing of evaluation bias for progression free survival endpoint in oncology clinical trials.

Stat Med. 2016-9-30

[6]

Model free audit methodology for bias evaluation of tumour progression in oncology.

Pharm Stat. 2015

[7]

Evaluation of discordance measures in oncology studies with blinded independent central review of progression-free survival using an observational error model.

J Biopharm Stat. 2013

[8]

Assessment of audit methodologies for bias evaluation of tumor progression in oncology clinical trials.

Clin Cancer Res. 2013-3-26

[9]

Discrepancies of assessments in a RECIST 1.1 phase II clinical trial - association between adjudication rate and variability in images and tumors selection.

Cancer Imaging. 2018-12-11

[10]

Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.

Eur J Cancer. 2011-3-22

引用本文的文献

[1]

Meta-Analysis of 49 Roche Oncology Trials Comparing Blinded Independent Central Review (BICR) and Local Evaluation to Assess the Value of BICR.

Oncologist. 2024-8-5

本文引用的文献

[1]

Exaggeration of PFS by blinded, independent, central review (BICR).

Ann Oncol. 2019-2-1

[2]

Evaluation of Blinded Independent Central Review of Tumor Progression in Oncology Clinical Trials: A Meta-analysis.

Ther Innov Regul Sci. 2013-3

[3]

Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour.

BMJ Open. 2018-9-10

[4]

Bias in progression-free survival analysis due to intermittent assessment of progression.

Stat Med. 2015-10-30

[5]

Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer.

Cancer. 2012-3-20

[6]

Censoring in survival analysis: Potential for bias.

Perspect Clin Res. 2012-1

[7]

Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer.

Curr Oncol. 2011-10

[8]

Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis.

Eur J Cancer. 2011-3-21

[9]

Blinded independent central review of the progression-free survival endpoint.

Oncologist. 2010

[10]

Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.

J Clin Oncol. 2009-4-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

Appropriate statistical methods are available to handle biases encountered in blinded, independent, central review (BICR) determined progression-free survival.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献